SOLASCURE Ltd (“SolasCure”), a biotechnology company developing a novel treatment to transform chronic wound care and the U.S. Army Institute of Surgical Research (“USAISR”), today announced a research collaboration to evaluate SolasCure’s investigational product, Aurase Wound Gel, as a means for managing combat wounds.
Novel urine-based prognostic model promises to transform bladder cancer treatment
In a study published in the journal Genes & Diseases, researchers from Fudan University, have developed a novel urine-based prognostic model that promises to transform
November 21, 2023